Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 4,943,791 | 2,086,515 | 1,716,497 | 2,155,952 | 1,563,098 | 12,465,853 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf .... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3 | 4,943,791 | 2,086,515 | 1,716,497 | 2,155,952 | 1,563,098 | 12,465,853 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) .. | 1,203,678 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 11,262,175 | |||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 4,943,791 | 2,086,515 | 1,716,497 | 2,155,952 | 1,563,098 | 12,465,853 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 102,997 | 123,025 | 930,288 | 1,032,490 | 1,391,020 | 3,579,820 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 46,493,405 | 46,493,405 | ||||
| 11 | Total support. Add lines 7 through 10 | 62,539,078 | |||||
Calendar year (or fiscal
year beginning in) ![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by 0.035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | |
| 4 Amounts paid to acquire exempt-use assets | 4 | |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | |
| 6 Other distributions (describe in Part VI). See instructions | 6 | |
| 7Total annual distributions. Add lines 1 through 6. | 7 | |
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
8 | |
| 9 Distributable amount for 2023 from Section C, line 6 | 9 | |
| 10 Line 8 amount divided by Line 9 amount | 10 | |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2023 |
(iii) Distributable Amount for 2023 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2023 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2023 (reasonable cause required-- explain in Part VI).
See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2023: | ||||
| a From 2018....... | ||||
| b From 2019....... | ||||
| c From 2020....... | ||||
| d From 2021....... | ||||
| e From 2022....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2023 distributable amount | ||||
|
i
Carryover from 2018 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | ||||
| 4Distributions for 2023 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2023 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | ||||
|
5
Remaining underdistributions for years prior to 2023, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2023. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2024. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2019..... | ||||
| b Excess from 2020..... | ||||
| c Excess from 2021..... | ||||
| d Excess from 2022..... | ||||
| e Excess from 2023..... | ||||
| Facts And Circumstances Test |
|---|
| SUMMARY OF FACTS AND CIRCUMSTANCES WHICH ESTABLISH THAT THE PROGERIA RESEARCH FOUNDATION (PRF) IS IN THE NATURE OF AN ORGANIZATION THAT IS PUBLICLY SUPPORTED.THE MISSION OF THE PROGERIA RESEARCH FOUNDATION (PRF) IS TO FIND TREATMENTS AND THE CURE FOR HUTCHINSON-GILFORD PROGERIA (PROGERIA) SYNDROME, A FATAL, ULTRA-RARE, "RAPID AGING" DISEASE THAT AFFLICTS CHILDREN WHO, WITHOUT TREATMENT, DIE AT AN AVERAGE AGE OF 14 YEARS.PRF HAS SOLICITED CONTRIBUTIONS FROM THE GENERAL PUBLIC FROM ITS INCEPTION IN 1999. PRF HAS REPORTED THE FOLLOWING PERCENTAGES OF PUBLIC SUPPORT FOR THE PAST 9 YEARS:2023 = 18.01%2022 = 19.66%2021 = 19.71%2020 = 74.45%2019 = 75.54%2018 = 86.54%2017 = 94.36%2016 = 94.36%2015 = 90.84%AS ILLUSTRATED ABOVE, PRIOR TO RECEIVING THE EXTRAORDINARY FUNDING IN 2021, PRF'S PERCENTAGE OF PUBLIC SUPPORT SIGNIFICANTLY EXCEEDED 33 1/3%. PRF CONTINUES ALL FUNDRAISING EFFORTS AND EXPECTS TO RETURN TO THE 33 1/3% OF PUBLIC SUPPORT IN THE COMING YEARS.NUMBER OF DONORS FOR THE PAST 9 YEARS:2023 = 2,1712022 = 2,4322021 = 2,4412020 = 2,7862019 = 3,2452018 = 3,6702017 = 3,8592016 = 4,1462015 = 4,097WITH A PROGRAM RATIO THAT IS APPROXIMATELY 80% EACH YEAR, PRF EXPENDS SUBSTANTIALLY ALL OF ITS ANNUAL INCOME FOR ITS EXEMPT PURPOSE AND DEPENDS ON THE FUNDS IT SOLICITS ANNUALLY FROM THE PUBLIC AS WELL AS ITS INVESTMENT INCOME TO SUPPORT THEIR PROGRAMS ON AN ONGOING BASIS. FOR ITS ENTIRE EXISTENCE PRF HAS BEEN RELENTLESSLY FOCUSED ON FINDING TREATMENTS AND THE CURE FOR PROGERIA.IN NOVEMBER 2020, FEDERAL FOOD AND DRUG ADMINISTRATION (FDA) APPROVAL WAS GRANTED FOR LONAFARNIB (ALSO KNOWN AS ZOKINVY) FOR THE TREATMENT OF PROGERIA. THE PRF-FUNDED CLINICAL DRUG TRIAL INVOLVING LONAFARNIB PROVIDED SIGNIFICANT DATA AND ANALYSIS FOR THE NEW DRUG APPLICATION (NDA) THAT LED TO APPROVAL. AS A DIRECT RESULT OF THIS APPROVAL, AND IN ACCORDANCE WITH THE FEDERAL FOOD, DRUG, AND COSMETIC ACT (FD&C ACT), THE FDA AWARDED A PRIORITY REVIEW VOUCHER (PRV) TO THE SPONSOR OF THIS RARE PEDIATRIC DISEASE PRODUCT NDA. IN 2021, PURSUANT TO A COLLABORATION AGREEMENT WITH THE SPONSOR, PRF RECEIVED PROCEEDS ON THE SALE OF THE PRV IN THE AMOUNT OF $46,493,405. IT IS THE INTENTION OF PRF TO USE THIS EXTRAORDINARY FUNDING TO SUPPORT THE NEXT GENERATION OF RESEARCH AND FUTURE DRUG TRIALS THAT WILL LEAD TO MORE ADVANCED TREATMENTS AND, ULTIMATELY, THE CURE FOR PROGERIA.ANNUALLY, PRF SOLICITS CONTRIBUTIONS FROM THE PUBLIC TO SUPPORT ITS ONGOING PROGRAMS AND SERVICES. FUNDRAISING EFFORTS INCLUDE THE FOLLOWING:A. VOLUNTEER-LED EVENTS (GOLF TOURNAMENTS, MOTORCYCLE RIDES, ETC.)B. AN ANNUAL 5K RUN, 2-MILE WALK RACE IN PEABODY, MA WITH 300 PARTICIPANTSC. THE ANNUAL FALMOUTH ROAD RACE, WITH A TEAM OF OVER 20 RUNNERSD. THE ANNUAL BOSTON MARATHON, WITH A 2 - 10 PESON TEAME. BI-ANNUAL GALA & AUCTION, INCLUDING 350 GUESTSF. BI-ANNUAL GOLF TOURNAMENT, WITH NEARLY 100 PLAYERSG. MAILING AND SOCIAL MEDIA CAMPAIGNS: MID-YEAR "ONE POSSIBLE AND END OF YEAR "GIVING TUESDAY", AMONG OTHERS.FUNDS RAISED ARE USED TO SUPPORT THE FOLLOWING PROGRAMS:A. ONGOING CLINICAL DRUG TRIAL AT BOSTON CHILDREN'S HOSPITALB. RESEARCH GRANTS FOR THE ADVANCEMENT OF DISEASE UNDERSTANDING AND TREATMENTC. RESEARCH FOR POTENTIAL FUTURE CLINICAL TRIALSD. THE PRF DIAGNOSTIC TESTING PROGRAME. THE PRF CELL & TISSUE BANKF. THE PRF MEDICAL & RESEARCH DATABASEG. PRF-ORGANIZED SCIENTIFIC CONFERENCESH. WEBSITE FOR PUBLIC AWARENESS AND COMMUNICATIONI. UPDATING AND DISTRIBUTION OF THE PROGERIA HANDBOOK - A TREATMENT GUIDE FOR FAMILIES AND HEALTH CARE PROVIDERS OF THOSE WITH PROGERIAJ. THE PRF INTERNATIONAL PROGERIA REGISTRYK. PRF'S TRANSLATION PROGRAML. DEVELOPMENT OF A BIOMARKER TO MEASURE THE DISEASE-CAUSING TOXIC PROTEIN, PROGERIN PRF HAS A TEN-MEMBER BOARD OF DIRECTORS. BOARD MEMBERS' PROFESSIONAL BACKGROUNDS INCLUDE THE LEGAL, ACCOUNTING, PUBLIC RELATIONS, EVENT PLANNING FIELDS AS WELL AS EXECUTIVE LEADERSHIP AND MANAGEMENT OF FOR-PROFIT BUSINESSES. THE BOARD PROVIDES OVERSIGHT OF OPERATIONS AND PROGRAMS TO ENSURE NO ACTIVITIES ARE FOR THE BENEFIT OF PRIVATE INTERESTS.ON AN ANNUAL BASIS, PRF NORMALLY RECEIVES A SUBSTANTIAL PART OF ITS SUPPORT FROM THE GENERAL PUBLIC, GOVERNMENT GRANTS, AND NET INVESTMENT EARNINGS. THE SUPPORT PRF RECEIVES IS USED TO CONTINUE THE MISSION TO DISCOVER TREATMENTS AND THE CURE FOR PROGERIA. IN 2021, PRF RECEIVED AN EXTRAORDINARY SOURCE OF SUPPORT THAT WAS THE RESULT OF DECADES-LONG RESEARCH AND OPERATION OF PRF'S RESEARCH-RELATED PROGRAMS. |
| Return Reference | Explanation |
|---|
| Software ID: | |
| Software Version: |
| Return Reference | Explanation |
|---|---|
| FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICES | DIAGNOSTIC TESTING: PRF DEVELOPED A DIAGNOSTIC TEST FOR PROGERIA IN THE WAKE OF THE 2003 GENE DISCOVERY SO THAT CHILDREN, THEIR FAMILIES AND MEDICAL CARETAKERS CAN FOR THE FIRST TIME BE GIVEN A DEFINITIVE SCIENTIFIC DIAGNOSIS. THIS CAN TRANSLATE INTO EARLIER DIAGNOSIS, FEWER MISDIAGNOSES AND EARLY MEDICAL INTERVENTION TO ENSURE A BETTER QUALITY OF LIFE FOR THE CHILDREN. MEDICAL & RESEARCH DATABASE: THE DATABASE IS A COLLECTION OF MEDICAL RECORDS OF PROGERIA PATIENTS FROM ALL OVER THE WORLD. THE DATA IS RIGOROUSLY ANALYZED TO DETERMINE THE BEST COURSE OF TREATMENTS TO IMPROVE THE PATIENTS' QUALITY OF LIFE. THIS INFORMATION IS INVALUABLE FOR THE ATTENDING PHYSICIAN TO GUIDE THE FAMILY THROUGH THE BEST COURSE OF ACTION. DATABASE MATERIAL WAS USED TO CREATE PRF'S COMPREHENSIVE HEALTHCARE RECOMMENDATIONS HANDBOOK ON PROGERIA AIMED AT OPTIMIZING QUALITY OF LIFE. THE DATABASE WAS ALSO CRITICAL IN DETERMINING THE PRIMARY CLINICAL OUTCOME PARAMETER FOR THE PROGERIA CLINICAL DRUG TRIALS. WEBSITE/PUBLIC AWARENESS: IN 2019, THE PRF WEBSITE WAS UPDATED. PROGERIARESEARCH.ORG PROVIDES VISITORS WITH ACCESS TO THE LATEST INFORMATION ON PROGERIA RESEARCH, SUPPORT, AND EDUCATION FOR FAMILIES AND CAREGIVERS. IN ADDITION, PRF'S SOCIAL MEDIA PRESENCE AND MEDIA EXPOSURE HELP RAISE AWARENESS OF THE ULTRA-RARE DISEASE GLOBALLY. PRF TRANSLATION PROGRAM: IN TOUCH WITH THE WORLD. WITH A PROMINENT GLOBAL OUTREACH, PRF ELIMINATES BARRIERS OF COMMUNICATION FOR PATIENTS AND THEIR FAMILIES AROUND THE WORLD. THIS INITIATIVE HAS SUCCEEDED IN TRANSLATING PRF PROGRAM AND MEDICAL CARE MATERIALS INTO OVER 38 DIFFERENT LANGUAGES. THE FOUNDATION EDITS AND PUBLISHES THE PROGERIA HANDBOOK, A GUIDE FOR FAMILIES AND HEALTH CARE PROVIDERS OF CHILDREN WITH PROGERIA. IT IS PUBLISHED IN ENGLISH AND SEVERAL OTHER LANGUAGES TO ALLOW ITS USE THROUGHOUT THE WORLD. THE FOUNDATION MAINTAINS AN INTERNATIONAL PROGERIA REGISTRY CONTAINING CENTRALIZED INFORMATION ON CHILDREN AND FAMILIES LIVING WITH PROGERIA. THIS ASSURES RAPID DISTRIBUTION OF ANY NEW INFORMATION THAT MAY BENEFIT THE CHILDREN. PRF ORGANIZES SCIENTIFIC CONFERENCES THAT BRING TOGETHER SCIENTISTS AND CLINICIANS FROM ALL OVER THE WORLD TO SHARE THEIR EXPERTISE AND CUTTING EDGE SCIENTIFIC DATA, AND FOSTER COLLABORATION IN THE FIGHT AGAINST PROGERIA AND OTHER AGING RELATED ILLNESSES. CLINICAL TRIALS 2023: IN 2023, 15 CHILDREN CAME TO BOSTON TO UNDERGO TESTING AND OBTAIN LONAFARNIB FOR THE PROLON 3 (LONAFARNIB EXTENSION) TRIAL, WHICH ALLOWS CHILDREN WHO ARE UNABLE TO OBTAIN LONAFARNIB IN THEIR HOME COUNTRY TO RECEIVE THIS LIFE EXTENDING TREATMENT THROUGH THIS TRIAL, WHILE ALSO GATHERING IMPORTANT DISEASE-RELATED DATA. OF THE 15 CHILDREN THREE WERE NAVE PATIENTS. ONE OF THE CHILDREN WHO CAME TO BOSTON FOR THE PROLON 3 TRIAL ALSO PARTICIPATED IN A FEASIBILITY STUDY, ALONG WITH TWO OTHER CHILDREN. IN JANUARY 2021, PRF REPORTED BREAKTHROUGH FINDINGS IN RNA THERAPEUTICS, WHEREIN THIS THERAPY INHIBITED PRODUCTION OF RNA CODING FOR THE PROGERIA DISEASE-CAUSING PROTEIN, PROGERIN. TYPICALLY, RNA THERAPEUTICS ARE LIQUIDS THAT ARE INJECTED INTRAVENOUSLY (DIRECTLY INTO THE VEIN). HOWEVER, THOSE WITH PROGERIA WOULD NOT BE ABLE TO TOLERATE INTRAVENOUS DELIVERY OF THE REQUIRED DAILY DOSAGE. THUS, PRF DEVELOPED A SUBCUTANEOUS DELIVERY SYSTEM WHEREBY THE LIQUID CAN BE INJECTED WITH A SMALL NEEDLE UNDER THE SKIN. A 6-MONTH STUDY TO DETERMINE THE FEASIBILITY OF THIS DELIVERY APPROACH FOR THOSE WITH PROGERIA BEGAN IN 2023. THE TEAM IS TESTING WHETHER ADMINISTRATION OF A SALINE SOLUTION CAN COMFORTABLY BE INJECTED SUBCUTANEOUSLY. |
| FORM 990, PART VI, SECTION A, LINE 2 | AUDREY GORDON WHO IS THE PRESIDENT IS THE SISTER OF LESLIE GORDON WHO IS THE VOLUNTEER MEDICAL DIRECTOR. SCOTT BERNS, WHO IS A DIRECTOR AND HUSBAND OF LESLIE GORDON (VOLUNTEER MEDICAL DIRECTOR), THE BROTHER-IN-LAW OF AUDREY GORDON (PRESIDENT). THE PRESIDENT ALSO SERVES AS PRF'S EXECUTIVE DIRECTOR. HER ROLE AS PRESIDENT, AS WITH ALL CORPORATE PRF OFFICERS, IS A VOLUNTEER POSITION; HER ROLE AS ED IS A PAID STAFF POSITION. |
| FORM 990, PART VI, SECTION B, LINE 11B | THE 990 IS REVIEWED BY THE PRESIDENT, EXECUTIVE DIRECTOR AND THE TREASURER. |
| FORM 990, PART VI, SECTION B, LINE 12C | DISCUSSED AT ANNUAL BOARD MEETINGS. |
| FORM 990, PART VI, SECTION B, LINE 15 | THE ED'S SALARY FOR 2023 WAS DETERMINED BY THE INDEPENDENT VOTING MEMBERS AFTER REVIEW OF THE DUTIES PERFORMED AND DATA AS TO COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS. THERE WERE NO OTHER COMPENSATED OFFICERS OR KEY EMPLOYEES IN 2023. |
| FORM 990, PART VI, SECTION C, LINE 19 | ALL DOCUMENTS ARE AVAILABLE UPON REQUEST, FINANCIAL STATEMENTS ARE ALSO AVAILABLE ON THE ORGANIZATION WEBSITE. |
| FORM 990, PART XII, LINE 2C: | THE ORGANIZATION HAS NOT CHANGED ITS OVERSIGHT PROCESS OR SELECTION PROCESS DURING THE TAX YEAR. |
| Software ID: | |
| Software Version: |